Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

NCT01980888 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01980888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01980888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
February 5, 2014
Completion date
June 16, 2016
Enrollment
311 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia